Quality of Life Study With Adalimumab in Rheumatoid Arthritis

Sponsor
Abbott
Study ID
NCT00234936
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of the study is to evaluate the ability of adalimumab combined with methotrexate to improve the quality of life in patients with active RA.

Key Dates

Start date
Dec 31, 2003
Status verified
Oct 2007

Study Design

Enrollment
200 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

QOL [ Time Frame: 12 months ]

Related Studies